Tandem Diabetes Care (TNDM) Accounts Payables (2016 - 2026)
Tandem Diabetes Care filings provide 13 years of Accounts Payables readings, the most recent being $47.1 million for Q4 2025.
- On a quarterly basis, Accounts Payables rose 5.22% to $47.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $47.1 million, a 5.22% increase, with the full-year FY2025 number at $47.1 million, up 5.22% from a year prior.
- Accounts Payables hit $47.1 million in Q4 2025 for Tandem Diabetes Care, down from $47.5 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $61.5 million in Q3 2022 to a low of $27.0 million in Q3 2021.
- Median Accounts Payables over the past 5 years was $48.0 million (2024), compared with a mean of $46.6 million.
- Biggest five-year swings in Accounts Payables: soared 128.12% in 2022 and later dropped 25.01% in 2023.
- Tandem Diabetes Care's Accounts Payables stood at $28.0 million in 2021, then soared by 98.81% to $55.7 million in 2022, then dropped by 11.02% to $49.6 million in 2023, then dropped by 9.79% to $44.7 million in 2024, then rose by 5.22% to $47.1 million in 2025.
- The last three reported values for Accounts Payables were $47.1 million (Q4 2025), $47.5 million (Q3 2025), and $55.8 million (Q2 2025) per Business Quant data.